Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Advancements in Hormone Receptor-Positive Metastatic Breast Cancer : Episode 2

      Navigating Treatment After Progression: Testing, ESR1 Mutations and Tolerable Options

      June 2, 2025
      By Virginia Kaklamani, MD, DSc
      Megan Kruse, MD
      Opinion
      Video

      Panelists discuss how to approach second-line therapy decisions for patients with metastatic breast cancer, emphasizing the importance of biomarker testing, including ESR1 mutations, and considering patient-specific factors.

      EP: 1.Understanding Cancer Changes and Testing: How Testing Guides Your Metastatic Breast Cancer Treatment

      Now Viewing

      EP: 2.Navigating Treatment After Progression: Testing, ESR1 Mutations and Tolerable Options

      EP: 3.Exploring a Patient Case: Biomarker Testing After Progression and Discussing Treatment Choices With Your Care Team

      EP: 4.EMERALD Trial Results: What Prior CDK4/6i Duration Means for Treatment Success

      EP: 5.Managing Elacestrant Treatment: From Patient Selection to Supportive Care

      EP: 6.Real-World Experience: The Efficacy and Tolerability of Oral Elacestrant for Patients with ESR1 Mutations

      EP: 7.Patient Education, Shared Decision-Making, and Optimizing Care for ESR1-Mutated Breast Cancer

      Video content above is prompted by the following:

      Clinical Brief: Biomarker Testing Strategy in Second-Line Therapy

      Main Discussion Topics:

      • Strategic approach to biomarker testing when transitioning to second-line therapy
      • Importance of liquid biopsy versus tissue biopsy for ESR1 mutation detection
      • Role of PIK3CA and other pathway mutations in treatment selection
      • Shared decision-making process for selecting between multiple treatment options
      • Clinical assessment of endocrine sensitivity duration as a treatment predictor

      Key Points for Physicians:

      • Liquid biopsy preferred for ESR1 mutation detection due to subclonal nature (15%-20% better detection)
      • PIK3CA mutations are clonal and detectable in the initial tissue biopsy
      • Prior CDK4/6 inhibitor response duration greater than 12 months indicates endocrine sensitivity
      • Multiple treatment options require individualized patient assessment
      • Quality-of-life considerations balance with efficacy outcomes

      The discussion emphasized that endocrine resistance is a complex phenomenon involving multiple pathways, not just ESR1 mutations, requiring comprehensive biomarker assessment for optimal treatment selection.

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Image of a woman with glasses in front of a blue background
      Image of a man in a suit smiling in front of an Oncology Nursing News background
      Image of a woman wearing a patterned shirt in front of a dark blue background
      Photo of a woman wearing a blazer in front of an Oncology Nursing News backdrop
      3 experts in this video
      3 experts in this video
      Photo of a white man with curly hair and in front of a blue Oncology Nursing News backdrop
      Related Content

      Anatomical graphic of a person with a tumor in their left breast

      First-Line T-DXd/Pertuzumab Yields Improved PFS in HER2+ mBC

      Russ Conroy
      June 4th 2025
      Article

      The combination of trastuzumab deruxtecan with pertuzumab shows promise as a standard of care for HER2-positive advanced breast cancer.


      Graphic of a breast with a tumor.

      Q&A: Strong Treatment Choices Can Build Trust in Patients With ESR1+ mBC

      Bridget Hoyt
      May 22nd 2025
      Article

      Selecting the right treatment path for a patient with an ESR1 mutation in metastatic breast cancer can help build trust.


      Line illustration of a breast on a yellow background

      How CDK4/6 Inhibitors Enable More Personalized Treatment in HR+ mBC

      Kimberly Podsada, BSN, RN, MSN, NP-C, CNS
      May 16th 2025
      Article

      The amount of CDK4/6-targeting treatment options available for patients with HR-positive breast cancer allows providers to personalize treatment.


      Illustration of two people in lab coats doing work at a desk and at a microscope with a breast icon behind

      Avutometinib Triplet Active in Resistant HR+/HER2– Breast Cancer

      Jax DiEugenio
      May 7th 2025
      Article

      Early trial data show 13.3% objective response with avutometinib, abemaciclib, and fulvestrant in HR+/HER2– breast cancer resistant to CDK4/6 inhibitors.


      Anatomic image of a breast

      T-DXd Plus Pertuzumab Improves PFS Over THP in HER2+ Metastatic Breast Cancer

      Ashling Wahner
      April 23rd 2025
      Article

      Side profile anatomical rendering of a person, with breast tissue and a breast tumor in orange

      Vepdegestrant Meets PFS End Point for Metastatic Breast Cancer Subtype

      Ashley Chan
      March 25th 2025
      Article
      Related Content

      Anatomical graphic of a person with a tumor in their left breast

      First-Line T-DXd/Pertuzumab Yields Improved PFS in HER2+ mBC

      Russ Conroy
      June 4th 2025
      Article

      The combination of trastuzumab deruxtecan with pertuzumab shows promise as a standard of care for HER2-positive advanced breast cancer.


      Graphic of a breast with a tumor.

      Q&A: Strong Treatment Choices Can Build Trust in Patients With ESR1+ mBC

      Bridget Hoyt
      May 22nd 2025
      Article

      Selecting the right treatment path for a patient with an ESR1 mutation in metastatic breast cancer can help build trust.


      Line illustration of a breast on a yellow background

      How CDK4/6 Inhibitors Enable More Personalized Treatment in HR+ mBC

      Kimberly Podsada, BSN, RN, MSN, NP-C, CNS
      May 16th 2025
      Article

      The amount of CDK4/6-targeting treatment options available for patients with HR-positive breast cancer allows providers to personalize treatment.


      Illustration of two people in lab coats doing work at a desk and at a microscope with a breast icon behind

      Avutometinib Triplet Active in Resistant HR+/HER2– Breast Cancer

      Jax DiEugenio
      May 7th 2025
      Article

      Early trial data show 13.3% objective response with avutometinib, abemaciclib, and fulvestrant in HR+/HER2– breast cancer resistant to CDK4/6 inhibitors.


      Anatomic image of a breast

      T-DXd Plus Pertuzumab Improves PFS Over THP in HER2+ Metastatic Breast Cancer

      Ashling Wahner
      April 23rd 2025
      Article

      Side profile anatomical rendering of a person, with breast tissue and a breast tumor in orange

      Vepdegestrant Meets PFS End Point for Metastatic Breast Cancer Subtype

      Ashley Chan
      March 25th 2025
      Article

      Latest Conference Coverage

      Relacorilant/Nab-Paclitaxel Is Convenient, Safe in Ovarian Cancer

      Neoadjuvant Nivolumab Regimen Improves OS in Resectable NSCLC

      Relacorilant Combo Boosts PFS in Resistant Ovarian Cancer

      Nivolumab/Ipilimumab To Be New MSI-H/dMMR mCRC Standard of Care

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.